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Abstract 
RATIONALE: Intrapleural therapy with tPA 10mg/DNase 5mg twice daily has been shown to 
successfully manage over 90% of patients with pleural infection without surgery in 
randomized and open-label series. The doses chosen are empirical and not established via 
dose-escalation studies.  Potential bleeding risks associated with intrapleural tPA and the 
drug costs remain important concerns for many clinicians. The ADAPT (Alteplase Dose 
Assessment for Pleural infection Therapy) project aims to investigate the efficacy and safety 
of dose de-escalation for intrapleural tPA.  
 
OBJECTIVES: To evaluate the efficacy and safety of a reduced starting dose regimen of 5mg 
tPA (with 5mg DNase) administered intrapleurally for pleural infection. 
 
METHODS: Consecutive patients with pleural infection treated with open-label tPA 
5mg/DNase 5mg were included from four participating centers in Australia, UK and New 
Zealand. Dose-escalation was permitted at the discretion of the attending physician. Data 
relating to treatment success, radiological and inflammatory changes (C-reactive protein), 
volume of fluid drained, length of hospital stay and treatment complications were extracted 
retrospectively.  
 
MEASUREMENTS AND MAIN RESULTS: 61 patients (41 male, age 57±16 years) with pleural 
infection were prescribed treatment with an intrapleural regimen of tPA 5mg (with DNase 
5mg). Most (n=58, 93.4%) were successfully treated without requiring surgery. Treatment 
success was corroborated by significant clearance of pleural opacities on chest radiography 
(from 42% [IQR 22-58] to 16% [8-31] of hemithorax, p<0.001), increase in pleural fluid 
drainage (from 175mL in the 24 hours preceding treatment to 2025mL [IQR 1247-2984] over 
72 hours of therapy, p<0.05) and a significant reduction in CRP (p<0.05). Seven patients 
(11.5%) had dose-escalation of tPA to 10mg; three patients underwent surgery. Three 
patients (4.9%) received blood transfusions for gradual pleural blood loss; none were 
hemodynamically compromised. Pain needing escalation of analgesia affected 36% of 
patients; none required cessation of therapy. 
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CONCLUSIONS: These pilot data show that the use of a starting dose of 5mg tPA (with 5mg 
DNase) given intrapleurally for treatment of pleural infection is safe and effective. This 
regimen should be tested in future randomized controlled trials. 
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INTRODUCTION 
 
Pleural infection hospitalises over 65,000 people in the UK and USA each year and its 
incidence continues to increase worldwide(1-4). Treatment involves evacuation of infected 
pleural fluid via chest tube drainage and antibiotics. However, one in four patients fail 
conventional therapy and require invasive surgery and/or succumb to their illness(5).  
 
Treatment failure is frequently due to inadequate drainage of the multi-loculated 
effusions that develop as a consequence of fibrin deposition within the infected pleural 
space. Thus, intrapleural fibrinolytic therapy to lyse pleural loculations has attracted 
ongoing interest since 1949(6) with small studies(7, 8) demonstrating reductions in surgical 
intervention rates. Subsequently, the MIST (Multi-Centre Intrapleural Sepsis Trial)-1, the 
largest randomised controlled trial of intrapleural fibrinolytics (streptokinase) failed to 
demonstrate any benefits over placebo for pleural infection. Similar results were found in 
the fibrinolytic only (tissue plasminogen activator (tPA)) arm of the MIST-2 trial(9, 10).  
 
Deoxyribonuclease (DNase) was recently found to decrease the viscosity of infected 
pleural fluid(11). Intrapleural therapy combining DNase and tPA, facilitated pleural fluid 
drainage in animal studies(12). In the MIST-2, 96% of patients who received intrapleural tPA 
10mg/DNase 5mg therapy were successfully treated without needing surgery(9). Similar 
success rates have been replicated in three open-label series (n=107, 73 and 55) using the 
same combination doses(13-15).  
 
However, the potential bleeding risks associated with tPA remains the major concern 
of many clinicians in choosing between tPA/DNase therapy and surgical drainage. tPA also 
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accounts for ~75% of the combined cost of tPA (10mg) and DNase (5mg) therapy in the USA, 
UK and Australia. 
 
tPA activates circulating plasminogen and the fibrinolytic cascade. When used for 
ischaemic stroke, intravenous administration of tPA (0.9mg/kg, max 90mg) is associated 
with significant risks of symptomatic intracranial hemorrhage (6.4%, vs 0.6% with 
placebo)(16, 17). Intrapleural administration of tPA (±DNase) at 10mg doses rarely causes 
systemic hemorrhage but pleural bleeding has been reported at rates between 1.8% and 
12%(13-15, 18).  
 
Bleeding risks are dose-dependent when tPA is administered intravenously. A recent 
small study suggested the same may apply to intrapleural tPA use. The study randomized 
patients to intrapleural treatment with 20mg tPA or urokinase and was un-blinded following 
serious pleural bleeds in 5 tPA-treated patients (28%)(18). The pleural bleeding rate 
decreased to 12% when the study continued with tPA at 10mg.  
 
The dosing regimen of tPA 10mg/DNase 5mg administered intrapleurally twice daily, 
used in MIST-2, has since been widely adopted(9, 13, 14). Interestingly, these drug doses 
were chosen empirically rather than determined from conventional phase I dose-escalation 
studies. Given the high clinical success rate with the tPA 10mg/DNase 5mg regimen, we 
hypothesized that lower doses of tPA (with DNase) could still provide similar treatment 
efficacy and may improve safety and reduce drug costs 
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The ADAPT (Alteplase Dose Assessment for Pleural infection Therapy) project aims to 
systematically investigate the efficacy and safety of dose de-escalation for intrapleural tPA 
instillation. In this first study of the ADAPT project, we report patient outcomes from 
participating centers which adopted a reduced starting dose regimen of 5mg tPA (with 5mg 
DNase) for intrapleural therapy for pleural infection.   
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METHODS 
Data were collected from Sir Charles Gairdner Hospital (SCGH), Perth, Australia 
(September 2014-June 2016), North Bristol NHS Trust, UK (March 2015-April 2016), Queen 
Elizabeth University Hospital (QEUH), Glasgow, UK (February-April 2016) and Wellington 
Regional Hospital, New Zealand (January-April 2016). The listed centers all employed tPA at 
5mg (with DNase 5mg) during the study period as the standard starting dose as part of their 
local protocols which allowed dose-escalation of tPA at the discretion of the attending 
physician. Data were extracted retrospectively from case-notes and hospital databases.  
 
All patients in this study were treated according to usual local practice and assessed 
daily for clinical improvement. Suitability and timing of tPA/DNase therapy and other 
management decisions were determined by patients’ attending physicians. All patients who 
were prescribed intrapleural tPA/DNase from each centre during the study period received 
a starting dose of 5mg tPA with 5mg DNase. Decisions regarding dose escalation of tPA or 
surgical intervention were made by the treating physicians and were recorded. The study 
was approved by the institutional review board of Sir Charles Gairdner Group Human 
Research Committee. The ethics committees of the remaining participating centers (NHS 
North Bristol Central and NHS Greater Glasgow and Clyde Regional Ethics Committees and 
New Zealand Health and Disability Ethics Committee) provided exemption for the project as 
it qualified as a retrospective audit and exempted from formal approval.  
 
Pleural infection was defined as in previous studies(9, 13). All patients had clinical 
presentations consistent with pleural infection and pleural fluid that fulfilled ≥1 of the 
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following characteristics: purulent fluid, pH ≤7.20, glucose ≤3mmol/L (≤55mg/dL), presence 
of micro-organism(s) on gram-stain and/or bacterial culture.  
 
Both tPA (5mg) and DNase (5mg) were diluted with 0.9% sodium chloride to 50mL and 
administered twice daily. The duration of treatment was determined by the attending 
physicians based on the clinical response to treatment. In three centers, tPA (Actilyse, 
Boehringher Ingelheim) was instilled intrapleurally via a chest tube which was then clamped 
for 40-60 minutes and then unclamped to allow fluid drainage for 40-60 minutes. The 
process was then repeated with DNase 5mg (Pulmozyme, Roche). In one center (n=5), both 
medications were instilled directly after each other before the tube was clamped.  
 
Case-notes were interrogated for patient demographics, comorbidities and major life-
limiting illness (defined as advanced cancer, end stage renal/liver disease, severe chronic 
obstructive pulmonary disease and heart failure), clinical observations, treatment and 
outcomes, surgical interventions, complications, and pleural fluid volume drained. 
Laboratory results especially inflammatory markers, pleural fluid biochemistry and 
microbiologic cultures were recorded. Data were collected during hospital admission and 
from routine outpatient clinic follow-up for 90 days. Chest radiographs (CXRs) were 
assessed for the area of pleural opacity occupied by the pleural effusion by one 
pulmonologist or radiologist using a validated method(9). The CXR immediately prior to 
tPA/DNase treatment was compared to the first CXR available at a minimum of 72 hours 
following the first dose of tPA/DNase and to the CXR at the completion of antibiotic therapy.  
Where a CXR was not available at the completion of antibiotic therapy, a CXR within 30 days 
after completion of the antibiotic course or the last available CXR during treatment was 
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assessed. 
 
Outcomes: 
The outcomes included were 
i) survival without surgical intervention for pleural infection at 30 and 90 days 
from initiation of therapy;  
ii) length of hospital stay (LOS) following initial dose of tPA/DNase; 
iii) percentage change in pleural opacity on chest radiograph  
iv) volume of pleural fluid drained; 
v) blood C-reactive protein (CRP) level; 
vi) complications including  
a. systemic bleeding,  
b. significant pleural bleeding defined as a decrease in blood haematocrit 
causing haemodynamic instability or requiring blood transfusion, and  
c. pain. 
 
Treatment success was defined as survival to hospital discharge and avoidance of 
surgical intervention for the 30 days following the initial dose of tPA/DNase. 
 
Statistical analysis:  
Statistical analyses were performed using SigmaPlot 12.5 (Systat Software, San Jose, 
CA). Results are presented as mean (SD) or median (IQR) based on normality of data. The 
Wilcoxon Signed-Rank test and paired t-test (for non-parametric and parametric data 
respectively) were used. Multiple group comparisons were performed using analysis of 
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variance (ANOVA) on-ranks, followed by Dunn’s post-hoc test. Significance was defined as 
p<0.05.  
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RESULTS 
A total of 61 patients (41 males) with a mean age of 57 (SD 16) years were included 
from SCGH (n=36), Bristol (n=16), QEUH (n=5) and Wellington Hospital (n=4).  Forty-two 
patients (69%) had ≥1 comorbidities of which 28% had a major life-limiting illness, Table 1.  
 
The median (IQR) number of days from hospital admission to chest-tube insertion was 
2 (1-5) days. Most (93%, n=57) patients received tPA/DNase therapy more than 24 hours 
following chest tube insertion; amongst whom 39% (n=24) started therapy ≥ 48 hours after 
tube insertion. The majority of patients (n=36, 59.0%) were treated with 12F chest-tubes, 
followed by 18F (n=10, 16.4%) and 32F (n=4, 6.5%) drains. In two cases, the drain size was 
not recorded. Eight patients (13%) had an indwelling pleural catheter (IPC) in situ prior to 
diagnosis with pleural infection; seven for malignant pleural effusion and one for refractory 
pleural effusion from congestive heart failure. Eight (13.1%) patients, including three with 
IPCs, had additional chest drains inserted for drainage.  
 
All patients met the criteria for pleural infection, Table 2. The mean CRP in the 24hrs 
preceding treatment was 225mg/L (SD 105) and 51% of patients were febrile during this 
same period. In 37% of patients, the pleural fluid contained pus and/or yielded positive 
bacterial culture. Positive microbial culture was reported in 21 (34%) patients, with five 
(8.2%) reported as polymicrobial, Table 3. All patients received broad-spectrum antibiotics 
such as piperacillin/tazobactam (n=34, 56%), amoxicillin/clavulanate (n=9) and meropenem 
(n=8). Vancomycin was used as adjunct antibiotics in five patients. In 11 (18%) patients, the 
antibiotics were escalated during the treatment course.  Patients required a median total of 
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28 (IQR 20-35) days of antibiotics which included 12 (IQR 8-19) days of intravenous 
antibiotics in hospital or at home.   
 
OUTCOMES 
Most (n=57; 93.4%) patients fulfilled our pre-defined criteria of ‘success’ which 
included survival to hospital discharge and avoidance of surgical intervention for 30 days 
following the initial dose of tPA/DNase. One patient subsequently died from advanced 
malignant mesothelioma 20 days following hospital discharge. Therefore, 91.8% (n=56) of 
patients were alive at 30 days and did not have surgery. Follow up at 90 days was available 
in 89.3% (n=50) of these patients, and confirmed resolution of pleural infection with all 
patients (100%) alive without requiring surgical intervention. The six (10.7%) remaining 
patients had a median follow-up of 52 (IQR 35-59) days at which time all were alive and did 
not require surgery. 
 
 Patients received a median of 6 (IQR 4-6) doses of intrapleural tPA/DNase. Clinical 
resolution resulting in early treatment discontinuation occurred in 36% of patients who 
required a median of 3 doses (IQR 2-4). Less than 5% (n=3) of patients in the study received 
more than six doses; of which two received 7 and one received 12. Seven patients (11.5%), 
including five patients with an IPC had their tPA dose escalated to 10mg during the course, 
on average after 3.3 doses.  
 
The median LOS was 7 (IQR 5-10) days for the entire cohort and for those successfully 
treated. The LOS was 8 (IQR 6-11.5) days for those who required dose escalation to 10mg 
tPA and 12 (11.5-13) days for those who needed surgery.  
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Treatment failures 
Three patients were referred to surgery; two due to persistent infection, one 
underwent video-assisted thoracoscopic surgery and another a mini-thoracotomy. The third 
patient had successful control of his infection with tPA/DNase treatment but was referred 
for open decortication of thick residual visceral pleural rind and resultant trapped lung.  
 
An 87-year-old man died following admission with severe pneumonia and a heavily 
loculated parapneumonic effusion. He received six doses of tPA 5mg/DNase 5mg with 
significant improvements on CXR and CRP levels.  However he had multi-organ failure and 
was palliated due to his frailty, comorbidities and finding of a necrotic subcarinal mass 
suspicious of cancer.   
 
Radiology 
Significant radiological improvements were observed with tPA/DNase treatment, Figure 1. 
The percentage of hemithorax occupied by pleural opacity reduced from 42% (median, IQR 
22-58) on baseline CXR to 16% (IQR 8-31) after ≥72hrs, p<0.001. The pleural opacity was 
reduced to 5.0% of the hemithorax (IQR 0.5-14.4) at day 30 (IQR 20-45) post-treatment 
initiation in the 54 (96%) patients where CXR was available. This value was further reduced 
to 3.8% (IQR 0.1-11.0%) when patients with an IPC in situ at presentation were excluded 
from the analysis.  
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Volume of pleural fluid drained 
The median (IQR) volume of pleural fluid drained in the 24 hours preceding treatment 
was 175mL (75-450) which increased to 1157mL (844-1756) in the first 24 hours of 
tPA/DNase treatment and 2025mL (1247-2984) at 72 hours, p <0.05, Figure 2.  
 
CRP 
The median CRP at baseline was 220mg/L (IQR 140-301) and decreased by 11% (IQR 0 
to -24%) on day 1 of tPA/DNase treatment, Figure 3. However, in 30% (n=16/53) of patients, 
the CRP remained greater than baseline at 48 hours.  By day 4 of treatment a median 
reduction in CRP of 45% from baseline was observed (95% CI, 37.9-56.8, p <0.05). By day 28 
(IQR 15-40), the CRP had reduced to 9.4 mg/L (IQR 3-25). 
 
Adverse events 
No systemic bleeding was reported in any patients. Three (4.9%) patients had blood 
transfusions; all were hemodynamically stable. Two had steadily decreasing blood 
hematocrit/hemoglobin levels, presumably from drainage of large quantities of hemorrhagic 
pleural fluid, which triggered a clinical decision for blood transfusion. The first patient 
drained 6000mL of heavily blood-stained fluid. Her hemoglobin dropped from 107g/L to 
73g/L over four days and was transfused two units of packed red cells. She made an 
otherwise uneventful recovery. The second patient had a long history of thrombocytopenia 
and was considered a high-risk candidate for surgery. She developed a hematoma at the 
chest tube insertion site which required a blood transfusion. She had ongoing infection. It 
was considered that tPA/DNase therapy offered lower risks than surgery and she received 
six doses of tPA/DNase which successfully eradicated the pleural infection. The hemoglobin 
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gradually decreased (92g/L to 72g/L over 7 days) without hemodynamic compromise. She 
received a total of five units of packed red cells. The third patient drained 2575mL of 
hemorrhagic fluid after the first three doses of tPA/DNase. Following the fourth dose, 
400mL of dark venous-looking blood was drained. The fluid had a hematocrit (0.36) similar 
to that of corresponding serum. Treatment was ceased and the blood loss stopped quickly 
after. He received one unit of packed red cells at the time as a preventive measure. He 
remained well and did not record any drop in serum hemoglobin. He was discharged home 
five days after the start of tPA/DNase therapy. 
 
Chest pain following tPA/DNase administration was common (36%) and responded to 
short term escalation analgesia or in frequency of opioid therapy in all patients. No patients 
ceased treatment as a result. 
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DISCUSSION 
 
Our data showed that intrapleural instillation at a starting dose of 5mg tPA (and 5mg 
DNase) for pleural infection appeared to have comparable efficacy and safety profile with 
published data of using higher tPA doses (Table 4). The majority of patients (93.4%) in the 
present study were successfully treated and avoided surgery for pleural infection. The 
clinical success was corroborated by significant improvements in radiographic clearance, 
pleural fluid drainage and inflammatory markers.  Treatment with a reduced tPA dose was 
well tolerated and the incidence of blood transfusions (<5% patients) was comparable to 
previous studies using ≥10mg tPA. Pleural blood loss was gradual and no patients developed 
hemodynamic instability.   
 
Pleural infection has a reported mortality of up to 20%(5). In the two largest 
randomized trials of pleural infection(9, 10), 25-30% of the patients in the control groups 
failed conventional treatment (systemic antibiotics and chest tube drainage) and required 
surgery. This contrasts the results from tPA/DNase therapy which cured over 90% of 
patients without surgery, and produced significantly better radiographic clearances and 
shorter LOS than conventional treatment. Although intrapleural tPA/DNase therapy has 
attracted strong interests worldwide, hesitation in its implementation exists in many 
centers, particularly of concerns over bleeding risks and drug costs.  
 
Doses of tPA used for intrapleural therapy range from 2mg to 100mg daily in 
published literature(19). A study in horses (n=25) who received treatment with intrapleural 
tPA for fibrinous pleuropneumonia demonstrated successful treatment with doses ranging 
from 0.375mg to 20mg of tPA despite typically weighing in excess of 400kg(20). In the MIST-
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2 protocol, tPA was administered at 10mg and DNase at 5mg, twice daily up to six doses. 
These doses were chosen empirically without support from prior dose-escalation studies. 
The pharmacokinetics of tPA following intrapleural delivery is unknown; likewise, the 
optimal amount of tPA required to lyze fibrinous loculations remains unclear.  
 
 Using a lower starting dose of intrapleural tPA has a number of potential advantages. 
The bleeding risks with tPA have been shown to be dose dependent following systemic 
administration, however only causally linked with intrapleural administration. Although the 
rate of intrapleural bleeding in our study was similar to studies of 10mg tPA, there remains a 
theoretical potential to reduce adverse events with lower doses in stronger powered 
studies. We have demonstrated similar treatment success, as measured by survival at 
discharge and avoidance of surgery at 30 days to other pragmatic studies using intrapleural 
10mg tPA (with 5mg DNase) (13-15). Finally, this reduced dosage regimen should reduce 
total drug costs. 
 
The ADAPT project aims to conduct stepwise dose de-escalation studies to establish 
the lowest effective dose for intrapleural tPA use in pleural infection. This first ADAPT study 
confirmed our hypothesis that a lower (5mg) starting dose of tPA provided treatment 
efficacy highly comparable with studies using higher tPA doses, Table 4. ADAPT-2 is 
underway to establish the efficacy of tPA 2.5mg/DNase 5mg as a starting regimen. Others 
have investigated alternatives to the tPA/DNase protocol, eg daily dosing, instilling both 
drugs simultaneously, use of other fibrinolytics etc(14, 15) . 
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Although not a direct comparison study, our patient cohort and their disease severity 
were very similar to those from prior studies. Most of our patients had significant 
comorbidity, and had complex pleural collections that failed to improve after initial 24 hours 
of drainage. Indeed, 93% had multi-loculated effusions on ultrasonography. The patients 
were recruited consecutively to minimize selection biases. The magnitude of the volume of 
fluid drained over 72 hours, rate of radiographic clearance and reduction in CRP from our 
study were highly comparable with open-label series using tPA 10mg/DNase 5mg (13).   
 
In total 89% of patients were successfully treated with tPA (5mg) without requiring 
dose-escalation – thus justifying using 5mg as a starting dose. Only in seven cases of our 
study did the clinicians raise the tPA dose to 10mg, these patients did not appear 
disadvantaged in their LOS and other outcomes.  
 
Bleeding has long been a concern of intrapleural fibrinolytic use. The growing clinical 
experiences suggest that tPA very seldom induces pleural ‘hemorrhage’, i.e. massive rapid 
bleeding causing hemodynamic compromise. Instead, intrapleural fibrinolytics (eg tPA), via a 
monocyte chemotactic protein (MCP)-1 mediated mechanism(21), stimulate production of 
large quantities (median 1.5 to 2.6L in published series) of hemorrhagic pleural fluid. 
Patients, especially those with significant comorbidity, may not be able to mount a 
hematopoietic response to compensate for the loss of red cells resulting in a gradual decline 
in haematocrit (21).  
 
The study has several limitations. The retrospective nature of our study prohibits 
comparison with the conventional 10mg tPA dose or with patients treated for pleural 
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infection who were not administered tPA/DNase therapy. Comparison studies with 10mg 
tPA are required once the lowest-effective dose of tPA is established through dose de-
escalation studies. Secondly, like most other studies on this subject, there were no standard 
criteria for defining which patient failed tPA/DNase therapy and required surgery. As a 
pragmatic study, these decisions were left to the attending physician. It is well known that 
local practice and protocols differ around the world on the threshold of referring patients to 
surgery. Nonetheless, the vast majority of our patients did not require surgery and their LOS 
were very comparable to surgical series. It is therefore unlikely that they have been 
subjected to unusually high threshold for proceeding to surgery. Thirdly, eight patients had 
IPC related pleural infection. These patients often have better outcomes compared with 
non-IPC related pleural infection (22), however were included in the analysis to avoid 
selection bias. The small number of patients within our cohort is unlikely to alter our 
conclusion but instead help inform the safety profile of the regimen. Lastly, the centers 
involved had all developed significant experience in the use of tPA/DNase and in pleural 
infection in general. It is difficult to determine if centers at the early learning phase can 
reproduce the same success rates.  
 
The treatment success for patients who received a reduced starting dosage of 
intrapleural tPA (5mg) and DNase (5mg) for pleural infection was 93%, with only 11% of 
patients requiring dose escalation to 10mg of tPA. These observational data provide 
evidence that a starting dose of 5mg tPA (with 5mg DNase) intrapleurally for pleural 
infection is safe and effective. The findings of this hypothesis generating study will need to 
be prospectively evaluated in future randomized clinical trials against higher published dose 
regimens.  
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Table 1: Patient comorbidities 
 
Comorbidity n (%) 
Current cancer:   
Malignant mesothelioma 
Non-small cell lung cancer 
Ovarian 
Haematological 
Colon 
13 (21.3%) 
6 (9.8%) 
2 (3.2%) 
2 (3.2%) 
2 (3.2%) 
1 (1.6%) 
Endocrine: 
Type 2 diabetes mellitus 
Type 1 diabetes mellitus 
11 (18.0%) 
10 (16.4%) 
1 (1.6%) 
Respiratory: 
Asthma 
Severe chronic obstructive pulmonary disease (FEV1 <50%) 
11 (18.0%) 
9 (14.7%) 
2 (3.3%) 
Cardiovascular: 
Ischemic heart disease 
Congestive cardiac failure 
Atrial fibrillation 
10 (16.4%) 
6 (9.8%) 
3 (4.9%) 
1 (1.6%) 
Renal disease 8 (13.1%) 
Previous cancer: 
Breast carcinoma 
Non-Hodgkin’s lymphoma 
Small Cell Lung cancer 
Pancreatic carcinoma 
7 (11.5%) 
3 (4.9%) 
2 (3.3%) 
1 (1.6%) 
1 (1.6%) 
Liver Disease: 
Cirrhosis 
Alcohol 
Autoimmune 
5 (8.2%) 
2 (3.3%) 
1 (1.6%) 
2 (3.3%) 
Neurological: 
Cerebrovascular accident 
2 (3.3%) 
2 (3.3%) 
Gastrointestinal: 
Inflammatory bowel disease 
1 (1.6%) 
1 (1.6%) 
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Table 2: Pleural infection characteristics 
 
 
Pleural characteristics  
Right side, n 36 (59%) 
Moderate-Large effusion (>2 rib spaces) on ultrasound, n 56/60 (93%) 
Ultrasound evidence of loculations, n 54/58 (93%) 
Bacteria identified in pleural fluid culture, n 21 (34%) 
Pleural fluid pH‡, mean (SD)  6.99 (0.24) 
Pleural fluid glucose‡ mmol/L, median (IQR) 0.9 (0.5-3.4) 
LDH‡ as fold increase of serum upper limit of normal, 
median (IQR) 
4.5 (2.5-11.0) 
 
IQR; interquartile range, SD; standard deviation, LDH; Lactate dehydrogenase, 
‡ Results for pH, glucose and LDH were available in 47, 50 and 55 patients respectively. Three 
patients did not have any pleural biochemistry available. 
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Table 3: Microbiological of pleural fluid cultures 
 
 
Aerobes  
Staphylococcus 
Staphylococcus aureus 
Coagulase negative staphylococcus 
6 (9.8%) 
2 (3.3%) 
4 (6.6%) 
Streptococcus   
Streptococcus intermedius 
Streptococcus pneumoniae 
Streptococcus agalactiae 
5 (8.2%) 
3 (4.9%) 
1 (1.6%) 
1 (1.6%) 
Enterococcus spp. 3 (4.9%) 
3 (4.9%) 
Gram negative 
Pseudomonas spp. 
Acinetobacter spp. 
Coliform bacteria 
9 (14.8%) 
4 (6.6%) 
1 (1.6%) 
4 (6.6%) 
Anaerobes  
Anaerobes 
Actinomyces meyeri 
Clostridium perfingens 
Bacteroides spp. 
Mixed anaerobic 
6 (9.8%) 
1 (1.6%) 
1 (1.6%) 
1 (1.6%) 
3 (4.9%) 
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Table 4: Summary of outcomes from published studies of intrapleural 10mg tPA with 5mg 
DNase for pleural infection 
 
 
n= 
Treatment 
success 
(%) 
Surgery 
n (%) 
LOS 
median 
(IQR) 
Death at 
30 days††† 
n (%) 
Pleural 
bleed 
n (%) 
Current study 
tPA 5mg (DNase 5mg) 
61 93.4 3 (4.9) 7 (5-10) 1 (1.6) 3 (4.9) 
Rahman et al. (9) 
NEJM 2011  
48 96† 2 (4.2) 11.8± 9.4 
(mean±SD) 
4 (8.3)†† 2 (4.2) 
Piccolo et al. (13) 
Ann Am Thorac Soc 2014  
107 92.3 8 (7.5) 10 (6-17) 3 (2.8) 2 (1.8) 
Mehta et al.a (15) 
Respiration  2016 
55 92.7 4 (7.3) 13 (11-18) 3 (5.5) 0 (0.0) 
Majid et al. (14) 
Ann Am Thorac Soc 2016 
73 90.4 7 (9.6) 7 (5-11) 2 (2.7)* 4 (5.4) 
 
a tPA/DNase was administered once daily 
† Defined as the proportion of patients who did not require surgical intervention at 30 days and 
does not include deaths during admission (not reported) 
†† Cause of death not reported in study 
††† Death from any cause at 30 days. Majid et al. report deaths related to pleural infection only. 
* Death likely due to pleural infection 
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Figure 1: Change in pleural effusion size on chest radiograph (n=55) expressed as a 
percentage of the hemithorax area before 5mg tPA/DNase treatment (pre-treatment) and 
72 hours following the first dose of tPA/DNase (post-treatment). Six patients were excluded 
from analysis; three had extensive baseline changes secondary to mesothelioma and three 
patients did not have an CXR available at either baseline or within 48hrs post-treatment  
*** p<0.001, Wilcoxon Signed Rank Test. 
 
 
Figure 2: Cumulative volume of pleural fluid drained (n=60) in the 24 hours before 
treatment (-24 hrs) and at 24 and 72 hours following the first dose of tPA/DNase. 
***ANOVA on Ranks, p<0.05 by Dunn’s post-hoc test. 
 
 
Figure 3: Change in C-reactive protein over the course of tPA/DNase treatment. Baseline is 
the day prior to first dose tPA/DNase and is taken at 100%. *ANOVA on Ranks, p<0.05 by 
Dunn’s post-hoc test. 
 
 
 
  
 26 
References: 
 
1. Finley C, Clifton J, Fitzgerald JM, Yee J. Empyema: an increasing concern in Canada. Can 
Respir J 2008; 15: 85-89. 
2. Burgos J, Lujan M, Falcó V, Sánchez A, Puig M, Borrego A, Fontanals D, Planes AM, Pahissa 
A, Rello J. The Spectrum of Pneumococcal Empyema in Adults in the Early 21st 
Century. Clin Infect Dis 2011; 53: 254-261. 
3. Grijalva CG, Zhu Y, Nuorti JP, Griffin MR. Emergence of parapneumonic empyema in the 
USA. Thorax 2011; 66: 663-668. 
4. Li ST, Tancredi DJ. Empyema hospitalizations increased in US children despite 
pneumococcal conjugate vaccine. Pediatrics 2010; 125: 26-33. 
5. Davies HE, Davies RJO, Davies CWH. Management of pleural infection in adults: British 
Thoracic Society pleural disease guideline 2010. Thorax 2010; 65: ii41-ii53. 
6. Tillett WS, Sherry S. The Effect in Patients of Streptococcal Fibrinolysin (Streptokinase) 
and Streptococcal Desoxyribonuclease on Fibrinous, Purulent, and Sanguinous 
Pleural Exudations. J Clin Invest 1949; 28: 173-190. 
7. Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bolliger CT. Intrapleural 
streptokinase for empyema and complicated parapneumonic effusions. Am J Respir 
Crit Care Med 2004; 170: 49-53. 
8. Bouros D, Schiza S, Tzanakis N, Chalkiadakis G, Drositis J, Siafakas N. Intrapleural 
urokinase versus normal saline in the treatment of complicated parapneumonic 
effusions and empyema. A randomized, double-blind study. Am J Respir Crit Care 
Med 1999; 159: 37-42. 
9. Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, Peckham D, Davies CW, 
Ali N, Kinnear W, Bentley A, Kahan BC, Wrightson JM, Davies HE, Hooper CE, Lee YC, 
 27 
Hedley EL, Crosthwaite N, Choo L, Helm EJ, Gleeson FV, Nunn AJ, Davies RJ. 
Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N 
Engl J Med 2011; 365: 518-526. 
10. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, Gabe R, Rees GL, Peto 
TE, Woodhead MA, Lane DJ, Darbyshire JH, Davies RJ. U.K. Controlled trial of 
intrapleural streptokinase for pleural infection. N Engl J Med 2005; 352: 865-874. 
11. Simpson G, Roomes D, Heron M. Effects of streptokinase and deoxyribonuclease on 
viscosity of human surgical and empyema pus. Chest 2000; 117: 1728-1733. 
12. Zhu Z, Hawthorne ML, Guo Y, Drake W, Bilaceroglu S, Misra HL, Light RW. Tissue 
plasminogen activator combined with human recombinant deoxyribonuclease is 
effective therapy for empyema in a rabbit model. Chest 2006; 129: 1577-1583. 
13. Piccolo F, Pitman N, Bhatnagar R, Popowicz N, Smith NA, Brockway B, Nickels R, Burke 
AJ, Wong CA, McCartney R, Choo-Kang B, Blyth KG, Maskell NA, Lee YC. Intrapleural 
tissue plasminogen activator and deoxyribonuclease for pleural infection. An 
effective and safe alternative to surgery. Ann Am Thorac Soc 2014; 11: 1419-1425. 
14. Majid A, Kheir F, Folch A, Fernandez-Bussy S, Chatterji S, Maskey A, Fashjian M, Cheng G, 
Ochoa S, Alape D, Folch E. Concurrent Intrapleural Instillation of Tissue Plasminogen 
Activator and Deoxyribonuclease for Pleural Infection: A Single Center Experience. 
Ann Am Thorac Soc 2016; In Press. 
15. Mehta HJ, Biswas A, Penley AM, Cope J, Barnes M, Jantz MA. Management of 
Intrapleural Sepsis with Once Daily Use of Tissue Plasminogen Activator and 
Deoxyribonuclease. Respiration 2016; 91: 101-106. 
16. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables 
G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, 
 28 
Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A. The benefits and 
harms of intravenous thrombolysis with recombinant tissue plasminogen activator 
within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a 
randomised controlled trial. Lancet 2012; 379: 2352-2363. 
17. The National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Tissue 
Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med 1995; 333: 1581-
1588. 
18. Aleman C, Porcel JM, Alegre J, Ruiz E, Bielsa S, Andreu J, Deu M, Sune P, Martinez-
Sogues M, Lopez I, Pallisa E, Schoenenberger JA, Bruno Montoro J, de Sevilla TF. 
Intrapleural Fibrinolysis with Urokinase Versus Alteplase in Complicated 
Parapneumonic Pleural Effusions and Empyemas: A Prospective Randomized Study. 
Lung 2015; 193: 993-1000. 
19. Thommi G, Nair CK, Aronow WS, Shehan C, Meyers P, McLeay M. Efficacy and safety of 
intrapleural instillation of alteplase in the management of complicated pleural 
effusion or empyema. Am J Ther 2007; 14: 341-345. 
20. Tomlinson JE, Byrne E, Pusterla N, Magdesian KG, Hilton HG, McGorum B, Davis E, 
Schoster A, Arroyo L, Dunkel B, Carslake H, Boston RC, Johnson AL. The Use of 
Recombinant Tissue Plasminogen Activator (rTPA) in The Treatment of Fibrinous 
Pleuropneumonia in Horses: 25 Cases (2007-2012). 
21. Lansley SM, Cheah HM, Varano Della Vergiliana JF, Chakera A, Lee YC. Tissue 
plasminogen activator potently stimulates pleural effusion via a monocyte 
chemotactic protein-1-dependent mechanism. Am J Respir Cell Mol Biol 2015; 53: 
105-112. 
 29 
22. Fysh ET, Tremblay A, Feller-Kopman D, Mishra EK, Slade M, Garske L, Clive AO, Lamb C, 
Boshuizen R, Ng BJ, Rosenstengel AW, Yarmus L, Rahman NM, Maskell NA, Lee YC. 
Clinical outcomes of indwelling pleural catheter-related pleural infections: an 
international multicenter study. Chest 2013; 144: 1597-1602. 
 
 
 
 
